PT  - JOURNAL ARTICLE
AU  - Fogerson, Michelle
AU  - Tsitsiklis, Melina
AU  - Brimble, Elise
AU  - Brünger, Tobias
AU  - Arslan, Alexander R.
AU  - Nerrie, Jayne
AU  - Laberinto, Kim P.
AU  - Lacoste, Alix M.B.
AU  - Martin, Richard L.
AU  - Lal, Dennis
AU  - Pathmanathan, Jay
AU  - Brandon Westover, M.
AU  - Fitter, Nasha
AU  - Donoghue, Jacob
TI  - Electroencephalographic insights into variant function and clinical outcomes in <em>SCN2A</em> encephalopathy
AID  - 10.1101/2023.10.24.23296360
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.10.24.23296360
4099  - http://medrxiv.org/content/early/2023/10/25/2023.10.24.23296360.short
4100  - http://medrxiv.org/content/early/2023/10/25/2023.10.24.23296360.full
AB  - Neither phenotype nor genotype reliably predicts clinical disease severity or neurodevelopmental outcomes in SCN2A developmental and epileptic encephalopathy. In this study we examined the electroencephalographic (EEG) features of children with SCN2A variants to quantify the range of EEG abnormalities and link EEG biomarkers to developmental outcomes.We retrospectively analyzed data from a cohort of 28 children with SCN2A variants and employed a genetics-based consensus framework to infer the functional characterization of each subject’s SCN2A variant. Eleven subjects were predicted to have a gain-of-function variant, and 17 subjects a loss-of-function variant. Overall, variant classifications matched subject phenotypes. 493 EEG recordings from the 28 subjects were analyzed (ages 1 day to 16 years). In addition to the SCN2A recordings, normative data from 1230 children without an epilepsy diagnosis or epileptiform features based on neurologists’ review was analyzed (1704 EEG recordings, ages 0 days to 16 years). We detected interictal epileptiform discharges (IEDs) in the SCN2A recordings using Beacon’s automated IED detection algorithm. We characterized background spectral features by computing relative power in four frequency bands (delta=1-4Hz, theta=4-8Hz, alpha=8-13Hz, beta=13-30Hz) in recordings from both the SCN2A and control cohorts. Additionally, we determined whether each SCN2A recording was associated with a gross motor developmental delay based on reported attainment of gross motor milestones. We then used mixed effects logistic regression models to estimate the effect of EEG biomarkers on developmental delay.We characterized EEG abnormalities in the background spectral features of the SCN2A cohort compared to the controls and identified differences in EEG signatures between the subjects with gain- and loss-of-function variants. Additionally, we showed that background spectral features are correlated with motor developmental outcome when measured relative to age-matched neurotypical children. Furthermore, we showed that interictal epileptiform activity is correlated with delayed motor development in subjects with gain-of-function variants.Taken together, these findings suggest that EEG biomarkers can be used to identify neurological abnormalities that correlate both with SCN2A variants and measures of development. We demonstrate the potential value of EEG as a disease biomarker, and we highlight the potential of such biomarkers to both guide future invasive genetic therapies and to be used as diagnostic tools.Competing Interest StatementInvitae authors are current employees and shareholders of Invitae, which owns the medical record data extraction platform, Ciitizen. Beacon Biosignals authors are employees and shareholders of Beacon Biosignals, which owns the data used to develop the EEG analytic algorithms.Funding StatementBeacon Biosignals authors were funded by Beacon Biosignals. Invitae authors were funded by Invitae, Corp. TB and DL were funded by FamiliesSCN2A Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Pearl IRB gave Invitae ethical approval to collect and deidentify the data in this study, and WCG IRB waived ethical approval for subsequent analysis of the deidentified data.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data produced in the present work are proprietary and unable to be shared.